Diabetes & Endocrinology Clinical Trials Update: Week 14, 2026

Published April 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

This Phase 3 trial is testing two new weight management drugs, Cagrilintide and CagriSema, in children and adolescents who have excess body weight or obesity. The study aims to find safer and more effective ways to help young patients lose weight, which could improve their overall health and quality of life. The trial is recruiting participants worldwide and will continue for about 1.5 years, with an optional extension lasting nearly 5 years.

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

This Phase 3 trial is exploring how different doses of the combination medicine CagriSema work to help adults with overweight or obesity lose weight. If proven effective, this treatment could provide a new option for people struggling to reduce their body weight. The study is currently active but not recruiting, with results expected after about 1.5 years of treatment for each participant.

A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight

This Phase 3 trial is testing CagriSema, an injection treatment, to see if it helps people with overweight or obesity lose weight more effectively than current options. The study includes a long-term follow-up phase lasting up to two years to assess sustained benefits. It is active but not recruiting and is conducted in multiple countries, with results anticipated after the treatment period.

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

This Phase 3 clinical trial is testing a new weekly injection called NNC0487-0111 to see if it helps people with obesity maintain their weight loss over time. Maintaining weight loss is often a challenge, so this treatment could provide important support for long-term health improvements. The study plans to enroll 600 participants across several countries and is not yet recruiting.

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

This Phase 3 trial is testing a weekly injection called CagriSema for children and adolescents with type 2 diabetes. The goal is to find out if this treatment can better lower blood sugar levels and reduce body weight in young patients, which are crucial factors for managing diabetes. The study is currently recruiting participants worldwide and will run for about 15 months.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.